Ichnos Sciences SA
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 80
- Registration Number
- NCT05862012
- Locations
- 🇺🇸
Standford Cancer Institute, Palo Alto, California, United States
🇦🇺Concord Hospital, Concord, New South Wales, Australia
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Drug: ISB 1442 SC injection escalating dosesDrug: ISB 1442 SC injection at RP2D
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 29
- Registration Number
- NCT05427812
- Locations
- 🇺🇸
University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸The University of Chicago Medical Center (UCMC) Duchossois Center for Advanced Medicine (DCAM), Chicago, Illinois, United States
🇺🇸Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center - Main Campus, Detroit, Michigan, United States
Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Biological: ISB 1302 250 ng/kgBiological: ISB 1302 325 ng/kgBiological: ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22Biological: ISB 1302 escalating doses,1200 ng/kg D15,22Biological: ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22Biological: ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22Biological: ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22Biological: ISB 1302 at the MTD and/or RP2D dose
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 1
- Registration Number
- NCT03983395
- Locations
- 🇺🇸
Ichnos Investigational Site 3, Philadelphia, Pennsylvania, United States
🇺🇸Ichnos Investigational Site 1, Gilbert, Arizona, United States
🇺🇸Ichnos Investigational Site 4, Louisville, Kentucky, United States
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: ISB 830 - Part 2 Group 5Drug: ISB 830 - Part 1 Group 2Drug: ISB 830 - Part 1 Group 3Drug: Placebo - Part 1 Group 4Drug: ISB 830 - Part 1 Group 1Drug: Placebo - Part 2 Group 6
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 462
- Registration Number
- NCT03568162
- Locations
- 🇺🇸
Ichnos Investigational Site 144, Las Vegas, Nevada, United States
🇺🇸Ichnos Investigational Site 148, Lake City, Florida, United States
🇺🇸Ichnos Investigational Site 129, Birmingham, Alabama, United States
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Biological: ISB 1342
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 81
- Registration Number
- NCT03309111
- Locations
- 🇺🇸
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Duke Clinical Research Institute, Durham, North Carolina, United States
Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers
- Conditions
- HER2 Expressing Solid Tumours
- Interventions
- Drug: CD3/HER2 bispecific monoclonal antibody
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 36
- Registration Number
- NCT02829372
- Locations
- 🇺🇸
Glenmark Investigational Site 204, Fairway, Kansas, United States
🇩🇪Glenmark Investigational Site 103, Berlin, Germany
🇩🇪Glenmark Investigational Site 102, Cologne, Germany
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: GBR 830Biological: Placebo
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Ichnos Sciences SA
- Target Recruit Count
- 64
- Registration Number
- NCT02683928
- Locations
- 🇺🇸
Glenmark Investigational Site 5, Los Angeles, California, United States
🇺🇸Glenmark Investigational Site 14, Rogers, Arkansas, United States
🇺🇸Glenmark Investigational Site 15, Tampa, Florida, United States